HPB Surgery

Review Article

Selective Interarterial Radiation Therapy (SIRT) in Colorectal Liver Metastases: How Do We Monitor Response?

Table 3

Radiological response.
StudyNumber of patientsExtra hepatic disease allowedChemotherapy
treatment		Radiologic staging methodTime to restaging CT (months)Time to restaging
PET (months)		Staging criteriaComplete response %Partial response %Stable disease %Curative treatment %Median survival
(months)		Median survival From radioembolisation
(months)
Anderson
et al. [21]		7NoPretreatment >1 month since last courseCT2NAOWN0086NRNR11
Andrews
et al. [34]		17NoPretreatment with 5FU or HAC FUDRCT4NAWHO02929NRNR13.8
Gray
et al. [30]		36NoConcurrent HAC FUDR
Nonprotocol also received		CT3*NAWHO64428NRNR17.0
Wong
et al. [16]		8YesPretreatment with 5FU, LV, and IrinotecanCT
PET		33WHOCT 11
PET 58		CT 16
PET 37		CT 16
PET 5		NRNRNR
Lim
et al. [3]		32Yes#Concurrent 5FUCT2NARECIST03128NRNRNR
Murthy
et al. [29]		9YesVariable pretreatment regimesCT
MR
PET		NRNRRECIST0056NR24.64.5
Lewandowski
et al. [35]		27NoPretreatment with capecitabine, 5FU, LV, irinotecan, or oxaliplatinCT
PET		33WHO0CT 35
PET 83		CT 52
NRNR9.3
Mancini
et al. [36]		35NRPretreatment based on oxaliplatinor irinotecanCT1.5NARECIST012.575NRNRNR
Kennedy
et al. [24]		208Yes#Pretreatment based on oxaliplatinor irinotecanCT
PET		33WHO03555NRNR10.5
Stubbs
et al. [22]		100YesConcurrent HAC 5FUCT3NAOWN17320NR16.211
Boppudi
et al. [23]		54No+Concurrent HAC 5FUCT3NAOWN
WHO		9.3
1.9		76
14.8		NRNRNR14.1
Jakobs
et al. [37]		18No+NRCT2–4NARECIST076% any responseNRNRNRNR
Sharma
et al. [5]		20YesConcurrent Folfox4CT3NARECIST0901010% (resection)NR9.3
van Hazel
et al. [38]		23Yes#Concurrent IrinotecanCT3NARECIST048391312.2NR
Hoffmann
et al. [6]		21NoVariable pretreatment regimesCT3NARECIST0NRNR5% (RFA)NRNR
Cosimelli
et al. [15]		50Yes★Pretreatment based on oxaliplatinor irinotecanCT1.5NARECIST222244% (resection)NM12.6
Chua
et al. [33]		140 Yes◯NRCT6NARECIST13131NR9NR
Nace
et al. [31]		51Yes#Prior treatment with various regimesCT
PET		33RECIST01364  10.2
Kosmider
et al. [32]		19 Yes⊛FOLFOX or 5FUCT2NARECIST117455% disease free at 6 years29.410.4
NA: not applicable, NR: not recorded, HAC: hepatic artery chemotherapy, FUDR: floxuridine, 5FU: 5-fluorouracil, LV: leucovorin, FOLFOX: 5-fluorouracil, leucovorin, oxaliplatin, FOLFOX4: oxaliplatin cycle 4–12, fluorouracil, leucovorin.
*Limited by government funding, #if liver dominant site of disease, +if present counted as relative contraindication, ★limited allowed: ≤3 nodules in the same extra hepatic organ each, nodule <3 mm as assessed by a 64 slice ct [15], ◯limitedextrahepatic metastases at on site such as a solitary pulmonary metastases,⊛limitedpulmonary nodules or abdominal lymphadenopathy.